The reduction of oxidative stress by nanocomposite Fullerol decreases mucositis severity and reverts leukopenia induced by Irinotecan

Pharmacological Research

Volumn 107, Issue , 2016, Pages 102-110

  Arifa, Raquel Duque Nascimento ^a,b   Paula, Talles Prosperi De ^a,b   Madeira, Mila Fernandes Moreira ^a,b   Lima, Renata Lacerda ^a,b   Garcia, Zélia Menezes ^a,b   Ávila, Thiago Vinícius ^a,b   Pinho, Vanessa ^b,c   Barcelos, Lucíola Silva ^d   Pinheiro, Maurício Veloso Brant ^d   Ladeira, Luiz Orlando ^d   Krambrock, Klaus ^d   Teixeira, Mauro Martins ^b   Souza, Danielle Glória ^a,b,d  

^a Laboratório de Interação Microrganismo Hospedeiro   (Brazil)

^b Departamento de Bioquímica e Imunologia   (Brazil)

^c Departamento de Morfologia   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Enterocytes; Fullerol; Leukopenia; Mucositis; ROS; Tumor

Indexed keywords

APOCYNIN; FULLEROL; GLUTATHIONE; INTERLEUKIN 1BETA; IRINOTECAN; MYELOPEROXIDASE; NANOCOMPOSITE; REACTIVE OXYGEN METABOLITE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; FULLERENE DERIVATIVE; PEROXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; EOSINOPHIL; HISTOPATHOLOGY; ILEUM; INTESTINE CELL; INTESTINE INJURY; INTESTINE ULCER; LEUKOPENIA; MALE; MELANOMA; MOUSE; MUCOSA INFLAMMATION; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TUMOR GROWTH; WEIGHT CHANGE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; INTESTINE MUCOSA; METABOLISM; MUCOSITIS; PATHOLOGY; TRANSGENIC MOUSE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; FULLERENES; GLUTATHIONE; ILEUM; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; LEUKOPENIA; MALE; MELANOMA; MICE, INBRED C57BL; MICE, TRANSGENIC; MUCOSITIS; NANOCOMPOSITES; OXIDATIVE STRESS; PEROXIDASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR BURDEN;

EID: 84961774521     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.03.004     Document Type: Article

References (67)

1. V. Boige, J. Taieb, M. Hebbar, D. Malka, T. Debaere, L. Hannoun, E. Magherini, D. Mignard, T. Poynard, and M. Ducreux Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level Eur. J. Cancer 42 2006 456 459
2. S.H. Park, S.M. Bang, E.K. Cho, J.H. Baek, J.H. Oh, S.A. Im, Y.S. Park, D.B. Shin, and J.H. Lee First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer Oncology 66 2004 353 357
3. N. Assy, W. Basher, L. Chetver, J. Shnaider, and J. Zidan First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: A phase II study J. Clin. Gastroenterol. 46 2012 e27 3
4. J.M. Bowen, R.J. Gibson, A.M. Stringer, T.W. Chan, A.S. Prabowo, A.G. Cummins, and D.M. Keefe Role of p53 in irinotecan-induced intestinal cell death and mucosal damage Anticancer Drugs 18 2007 197 210
5. A. Sevinc, M.E. Kalender, M. Altinbas, M. Ozkan, M. Dikilitas, and C. Camci Irinotecan as a second-line monotherapy for small cell lung cancer Asian Pac. J. Cancer Prev. 12 2011 1055 1059
6. L. Mineur, R. Sabatier, S. Kirscher, F. Plat, Y. Goubely, and N. Molinari Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan? A monocentric institution safety analysis of 46 patients Clin. Res. Hepatol. Gastroenterol. 35 2011 125 131
7. S.T. Sonis The pathobiology of mucositis Nat. Rev. Cancer 4 2004 277 284
8. R.D. Arifa, M.F. Madeira, T.P. de Paula, R.L. Lima, L.D. Tavares, Z. Menezes-Garcia, C.T. Fagundes, M.A. Rachid, B. Ryffel, D.S. Zamboni, M.M. Teixeira, and D.G. Souza Inflammasome activation is reactive oxygen species dependent and mediates irinotecan-Induced mucositis through IL-1beta and IL-18 in mice Am. J. Pathol. 184 2014 2023 2034
9. J. Grebowski, P. Kazmierska, and A. Krokosz Fullerenol - properties and applications in biomedical sciences Postepy Hig. Med. Dosw. (Online) 67 2013 859 872
10. R. Injac, M. Perse, M. Boskovic, V. Djordjevic-Milic, A. Djordjevic, A. Hvala, A. Cerar, and B. Strukelj Cardioprotective effects of fullerenol C(60)(Oh)(24) on a single Dose doxorubicin-induced cardiotoxicity in rats with malignant neoplasm Technol. Cancer Res. Treat. 7 2008 15 25
11. S. Trajkovic, S. Dobric, V. Jacevic, V. Dragojevic-Simic, Z. Milovanovic, and A. Dordevic Tissue-protective effects of fullerenol C60(OH) 24 and amifostine in irradiated rats Colloids Surf. B Biointerfaces 58 2007 39 43
12. S.M. Mirkov, A.N. Djordjevic, N.L. Andric, S.A. Andric, T.S. Kostic, G.M. Bogdanovic, M.B. Vojinovic-Miloradov, and R.Z. Kovacevic Nitric oxide-scavenging activity of polyhydroxylated fullerenol, C60(OH) 24 Nitric Oxide 11 2004 201 207
13. F. Lao, W. Li, D. Han, Y. Qu, Y. Liu, Y. Zhao, and C. Chen Fullerene derivatives protect endothelial cells against NO-induced damage Nanotechnology 20 2009 225103
14. R. Injac, M. Perse, M. Cerne, N. Potocnik, N. Radic, B. Govedarica, A. Djordjevic, A. Cerar, and B. Strukelj Protective effects of fullerenol C60(OH) 24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer Biomaterials 30 2009 1184 1196
15. N. Ikuno, H. Soda, M. Watanabe, and M. Oka Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum J. Natl. Cancer Inst. 87 1995 1876 1883
16. M. Skarn, M.C. Eike, T.J. Meza, I.S. Mercy, K.S. Jakobsen, and R.B. Aalen An inverted repeat transgene with a structure that cannot generate double-stranded RNA, suffers silencing independent of DNA methylation Transgenic Res. 15 2006 489 500
17. P.T. Bernardes, B.M. Rezende, C.B. Resende, T.P. De Paula, A.C. Reis, W.A. Goncalves, E.G. Vieira, M.V. Pinheiro, D.G. Souza, M.G. Castor, M.M. Teixeira, and V. Pinho Nanocomposite treatment reduces disease and lethality in a murine model of acute graft-versus-host disease and preserves anti-tumor effects PLoS One 10 2015 e0123004
18. R.B. Sardenberg, C.E. Teixeira, M. Pinheiro, and J.M. Figueiredo Nonlinear conductivity of fullerenol aqueous solutions ACS Nano 5 2011 2681 2686
19. D.G. Souza, S.F. Coutinho, M.R. Silveira, D.C. Cara, and M.M. Teixeira Effects of a BLT receptor antagonist on local and remote reperfusion injuries after transient ischemia of the superior mesenteric artery in rats Eur. J. Pharmacol. 403 2000 121 128
20. M.L. Melo, G.A. Brito, R.C. Soares, S.B. Carvalho, J.V. Silva, P.M. Soares, M.L. Vale, M.H. Souza, F.Q. Cunha, and R.A. Ribeiro Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: Effect of pentoxifylline and thalidomide Cancer Chemother. Pharmacol. 61 2008 775 784
21. D.G. Souza, A.C. Soares, V. Pinho, H. Torloni, L.F. Reis, M.M. Teixeira, and A.A. Dias Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury Am. J. Pathol. 160 2002 1755 1765
22. B. Usselmann, M. Newbold, A.G. Morris, and C.U. Nwokolo Deficiency of colonic telomerase in ulcerative colitis Am. J. Gastroenterol. 96 2001 1106 1112
23. H. Ohkawa, N. Ohishi, and K. Yagi Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction Anal. Biochem. 95 1979 351 358
24. J. Sedlakand, and R.H. Lindsay Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent Anal. Biochem. 25 1968 192 205
25. Y. Xie, F. Nassir, J. Luo, K. Buhman, and N.O. Davidson Intestinal lipoprotein assembly in apobec-1-/- mice reveals subtle alterations in triglyceride secretion coupled with a shift to larger lipoproteins Am. J. Physiol. Gastrointest. Liver Physiol. 285 2003 G735 G746
26. F.A. Amaral, V.V. Costa, L.D. Tavares, D. Sachs, F.M. Coelho, C.T. Fagundes, F.M. Soriani, T.N. Silveira, L.D. Cunha, D.S. Zamboni, V. Quesniaux, R.S. Peres, T.M. Cunha, F.Q. Cunha, B. Ryffel, D.G. Souza, and M.M. Teixeira NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout Arthritis Rheum. 64 2012 474 484
27. I. Vapa, V.M. Torres, A. Djordjevic, V. Vasovic, B. Srdjenovic, V.D. Simic, and J.K. Popovic Effect of fullerenol C(60)(OH) (24) on lipid peroxidation of kidneys: Testes and lungs in rats treated with doxorubicine Eur. J. Drug Metab. Pharmacokinet. 37 2012 301 307
28. B. Srdjenovic, V. Milic-Torres, N. Grujic, K. Stankov, A. Djordjevic, and V. Vasovic Antioxidant properties of fullerenol C60(OH) 24 in rat kidneys, testes, and lungs treated with doxorubicin Toxicol. Mech. Methods 20 2010 298 305
29. V.M. Torres, B. Srdjenovic, V. Jacevic, V.D. Simic, A. Djordjevic, and A.L. Simplicio Fullerenol C60(OH) 24 prevents doxorubicin-induced acute cardiotoxicity in rats Pharmacol. Rep. 62 2010 707 718
30. R. Injac, N. Radic, B. Govedarica, M. Perse, A. Cerar, A. Djordjevic, and B. Strukelj Acute doxorubicin pulmotoxicity in rats with malignant neoplasm is effectively treated with fullerenol C60(OH) 24 through inhibition of oxidative stress Pharmacol. Rep. 61 2009 335 342
31. M. Roursgaard, S.S. Poulsen, C.L. Kepley, M. Hammer, G.D. Nielsen, and S.T. Larsen Polyhydroxylated C60 fullerene (fullerenol) attenuates neutrophilic lung inflammation in mice Basic Clin. Pharmacol. Toxicol. 103 2008 386 388
32. H. Liu, X. Yang, Y. Zhang, A. Dighe, X. Li, and Q. Cui Fullerol antagonizes dexamethasone-induced oxidative stress and adipogenesis while enhancing osteogenesis in a cloned bone marrow mesenchymal stem cell J. Orthop. Res. 30 2012 1051 1105
33. X. Cai, H. Jia, Z. Liu, B. Hou, C. Luo, Z. Feng, W. Li, and J. Liu Polyhydroxylated fullerene derivative C(60)(OH)(24) prevents mitochondrial dysfunction and oxidative damage in an MPP(+) - induced cellular model of Parkinson's disease J. Neurosci. Res. 86 2008 3622 3634
34. V.D. Milic, K. Stankov, R. Injac, A. Djordjevic, B. Srdjenovic, B. Govedarica, N. Radic, V.D. Simic, and B. Strukelj Activity of antioxidative enzymes in erythrocytes after a single Dose administration of doxorubicin in rats pretreated with fullerenol C(60)(OH)(24) Toxicol. Mech. Methods. 19 2009 24 28
35. N.A. Monteiro-Riviere, K.E. Linder, A.O. Inman, J.G. Saathoff, X.R. Xia, and J.E. Riviere Lack of hydroxylated fullerene toxicity after intravenous administration to female Sprague-Dawley rats J. Toxicol. Environ. Health A 75 2012 367 373
36. R. Injac, M. Prijatelj, and B. Strukelj Fullerenol nanoparticles: Toxicity and antioxidant activity Methods Mol. Biol. 1028 2013 75 100
37. P.E. Marques, A.G. Oliveira, R.V. Pereira, B.A. David, L.F. Gomides, A.M. Saraiva, D.A. Pires, J.T. Novaes, D.O. Patricio, D. Cisalpino, Z. Menezes-Garcia, W.M. Leevy, S.E. Chapman, G. Mahecha, R.E. Marques, R. Guabiraba, V.P. Martins, D.G. Souza, D.S. Mansur, M.M. Teixeira, M.F. Leite, and G.B. Menezes Hepatic DNA deposition drives drug-induced liver injury and inflammation in mice Hepatology 61 2015 348 360
38. D.J. McQuade, P.I. Dargan, J. Keep, and D.M. Wood Paracetamol toxicity: What would be the implications of a change in UK treatment guidelines? Eur. J. Clin. Pharmacol. 68 2012 1541 1547
39. P.T. Bernardes, B.M. Rezende, C.B. Resende, T.P. De Paula, A.C. Reis, W.A. Goncalves, E.G. Vieira, M.V. Pinheiro, D.G. Souza, M.G. Castor, M.M. Teixeira, and V. Pinho Nanocomposite treatment reduces disease and lethality in a murine model of acute graft-versus-Host disease and preserves anti-tumor effects PLoS One 10 2015 e0123004
40. G. Bogdanovic, V. Kojic, A. Dordevic, J. Canadanovic-Brunet, M. Vojinovic-Miloradov, and V.V. Baltic Modulating activity of fullerol C60(OH) 22 on doxorubicin-induced cytotoxicity Toxicol. In Vitro 18 2004 629 637
41. R. Injac, M. Perse, N. Obermajer, V. Djordjevic-Milic, M. Prijatelj, A. Djordjevic, A. Cerar, and B. Strukelj Potential hepatoprotective effects of fullerenol C60(OH) 24 in doxorubicin-induced hepatotoxicity in rats with mammary carcinomas Biomaterials 29 2008 3451 3460
42. V.M. Torres, B. Srdjenovic, V. Jacevic, V.D. Simic, A. Djordjevic, and A.L. Simplicio Fullerenol C60(OH) 24 prevents doxorubicin-induced acute cardiotoxicity in rats Pharmacol. Rep. 62 2010 707 718
43. K. Yudoh, R. Karasawa, K. Masuko, and T. Kato Water-soluble fullerene (C60) inhibits the development of arthritis in the rat model of arthritis Int. J. Nanomed. 4 2009 217 225
44. R. Guabiraba, A.G. Besnard, G.B. Menezes, T. Secher, M.S. Jabir, S.S. Amaral, H. Braun, R.C. Lima-Junior, R.A. Ribeiro, F.Q. Cunha, M.M. Teixeira, R. Beyaert, G.J. Graham, and F.Y. Liew IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice Mucosal Immunol. 7 2016 1079 1093
45. A. Assa'ad Eosinophilic gastrointestinal disorders Allergy Asthma Proc. 30 2009 17 22
46. B.M. Yanand, and E.A. Shaffer Primary eosinophilic disorders of the gastrointestinal tract Gut 58 2009 721 732
47. A.T. Vieira, C.T. Fagundes, A.L. Alessandri, M.G. Castor, R. Guabiraba, V.O. Borges, K.D. Silveira, E.L. Vieira, J.L. Goncalves, T.A. Silva, M. Deruaz, A.E. Proudfoot, L.P. Sousa, and M.M. Teixeira Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis Am. J. Pathol. 175 2009 2382 2391
48. M.E. Rothenberg, A. Mishra, E.B. Brandt, and S.P. Hogan Gastrointestinal eosinophils Immunol. Rev. 179 2001 139 155
49. Y. Jungand, and M.E. Rothenberg Roles and regulation of gastrointestinal eosinophils in immunity and disease J. Immunol. 193 2014 999 1005
50. H.S. Lai, Y. Chen, W.J. Chen, J. Chang, and L.Y. Chiang Free radical scavenging activity of fullerenol on grafts after small bowel transplantation in dogs Transplant. Proc. 32 2000 1272 1274
51. R. Injac, M. Prijatelj, and B. Strukelj Fullerenol nanoparticles: Toxicity and antioxidant activity Methods Mol. Biol. 1028 2013 75 100
52. S.C. Regmi, S.Y. Park, S.K. Ku, and J.A. Kim Serotonin regulates innate immune responses of colon epithelial cells through Nox2-derived reactive oxygen species Free Radic. Biol. Med. 69 2014 377 389
53. F. Xie, S. Sun, A. Xu, S. Zheng, M. Xue, P. Wu, J.H. Zeng, and L. Bai Advanced oxidation protein products induce intestine epithelial cell death through a redox-dependent, c-jun N-terminal kinase and poly (ADP-ribose) polymerase-1-mediated pathway Cell Death Dis. 5 2014 e1006
54. I. Russo, A. Luciani, P. De Cicco, E. Troncone, and C. Ciacci Butyrate attenuates lipopolysaccharide-induced inflammation in intestinal cells and Crohn's mucosa through modulation of antioxidant defense machinery PLoS One 7 2012 e32841
55. A.S. Neishand, and R.M. Jones Redox signaling mediates symbiosis between the gut microbiota and the intestine Gut Microbes 5 2014 250 253
56. A. Alam, G. Leoni, C.C. Wentworth, J.M. Kwal, H. Wu, C.S. Ardita, P.A. Swanson, J.D. Lambeth, R.M. Jones, A. Nusrat, and A.S. Neish Redox signaling regulates commensal-mediated mucosal homeostasis and restitution and requires formyl peptide receptor 1 Mucosal Immunol. 7 2014 645 655
57. L.W. Petersonand, and D. Artis Intestinal epithelial cells: Regulators of barrier function and immune homeostasis Nat. Rev. Immunol. 14 2014 141 153
58. S.E. Winter, P. Thiennimitr, M.G. Winter, B.P. Butler, D.L. Huseby, R.W. Crawford, J.M. Russell, C.L. Bevins, L.G. Adams, R.M. Tsolis, J.R. Roth, and A.J. Baumler Gut inflammation provides a respiratory electron acceptor for Salmonella Nature 467 2010 426 429
59. S. Viaud, R. Daillere, I.G. Boneca, P. Lepage, P. Langella, M. Chamaillard, M.J. Pittet, F. Ghiringhelli, G. Trinchieri, R. Goldszmid, and L. Zitvogel Gut microbiome and anticancer immune response: Really hot Sh∗t! Cell Death Differ. 22 2015 199 214
60. A.M. Stringer, R.J. Gibson, R.M. Logan, J.M. Bowen, A.S. Yeoh, and D.M. Keefe Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats Cancer Biol. Ther. 7 2008 1919 1925
61. X.B. Lin, L.A. Dieleman, A. Ketabi, I. Bibova, M.B. Sawyer, H. Xue, C.J. Field, V.E. Baracos, and M.G. Ganzle Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats PLoS One 7 2012 e39764
62. X.B. Lin, A. Farhangfar, R. Valcheva, M.B. Sawyer, L. Dieleman, A. Schieber, M.G. Ganzle, and V. Baracos The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats PLoS One 9 2014 e83644
63. C.J. Chang, J.F. Lin, H.H. Chang, G.A. Lee, and C.F. Hung Lutein protects against methotrexate-induced and reactive oxygen species-mediated apoptotic cell injury of IEC-6 cells PLoS One 8 2013 e72553
64. T. Shiozawa, J. Tadokoro, T. Fujiki, K. Fujino, K. Kakihata, S. Masatani, S. Morita, A. Gemma, and N. Boku Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: A postmarketing survey Jpn. J. Clin. Oncol. 43 2016 483 491
65. B. Glimelius Benefit-risk assessment of irinotecan in advanced colorectal cancer Drug Saf. 28 2005 417 433
66. A.Y. Chen, P.M. Chen, and Y.J. Chen DNA topoisomerase I drugs and radiotherapy for lung cancer J. Thorac. Dis. 4 2012 390 397
67. H.A. Abbas, D.R. Maccio, S. Coskun, J.G. Jackson, A.L. Hazen, T.M. Sills, M.J. You, K.K. Hirschi, and G. Lozano Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity Cell Stem Cell 7 2010 606 617